
SciBac develops biotherapeutics using patented technology to treat chronic infections, focusing on cystic fibrosis.
Founded with a mission to revolutionize the treatment of chronic infections, SciBac leverages its patented MERGE platform to develop biotherapeutics that enhance beneficial microorganisms. The company's core focus is on treating antibiotic-resistant diseases, particularly chronic infections associated with cystic fibrosis. SciBac's innovative approach employs directed evolution to increase the therapeutic efficacy of its products, targeting pathogens such as Pseudomonas, Staph, Burkholderia, and NTM.
SciBac has garnered attention for its cutting-edge technology and impactful solutions in the biotherapeutics space. The company has received investments from notable venture capital firms and has formed strategic partnerships with leading research institutions. Key achievements include the development of its first two therapeutics specifically designed for cystic fibrosis-related infections. SciBac's work has the potential to significantly improve patient outcomes and address critical gaps in the treatment of antibiotic-resistant infections.

BioPlx

Microbion
microbioncorp.com

PhagePro
phageproinc.com

Petri Bio
petribio.com

Nextbiotics
next-biotics.com

Prokaryotics
prokaryotics.com

Bioharmony Therapeutics

X-Biotix Therapeutics

SmartPhage

Felix Biotechnology

Federation Bio
federation.bio

MarvelBiome
marvelbiome.com

ResBiotic
resbiotic.com

Resilient Biotics

Scioto Biosciences
Companies similar to SciBac include BioPlx, Microbion, PhagePro and Petri Bio.
SciBac was founded in 2015.
SciBac's headquarters is located in Burlingame, CA, US.
SciBac's most recent funding round was for $286.5k (USD) in July 2019.
As of Jul 9, 2019, SciBac has raised a total of $4M (USD).
SciBac has 5 employees as of Feb 5, 2024.